[Cardiovascular pharmacotherapy in the era of RNA-based precision medicine]
{{output}}
In the pharmacotherapy of heart failure with reduced ejection fraction (HFrEF) in addition to the "fantastic four", a potential fifth pillar is emerging with low-dose digitoxin, while finerenone broadens the spectrum of mineralocorticoid receptor antagonists... ...
